Health Catalyst, Inc. (NASDAQ:HCAT) Receives Average Rating of “Hold” from Brokerages

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been assigned an average rating of “Hold” from the thirteen ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $2.7727.

A number of equities research analysts have recently weighed in on HCAT shares. Weiss Ratings restated a “sell (e+)” rating on shares of Health Catalyst in a research report on Friday, March 27th. Cantor Fitzgerald restated a “neutral” rating on shares of Health Catalyst in a research report on Monday, May 11th. Wells Fargo & Company restated an “equal weight” rating and set a $1.00 target price (down from $5.00) on shares of Health Catalyst in a research report on Wednesday, March 18th. Stephens dropped their target price on Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Finally, Raymond James Financial set a $3.00 target price on Health Catalyst in a research report on Friday, March 13th.

Institutional Investors Weigh In On Health Catalyst

Large investors have recently modified their holdings of the business. Focus Partners Wealth bought a new stake in shares of Health Catalyst in the first quarter worth about $46,000. nVerses Capital LLC bought a new stake in shares of Health Catalyst in the fourth quarter worth about $25,000. Cresset Asset Management LLC bought a new stake in shares of Health Catalyst in the second quarter worth about $39,000. FNY Investment Advisers LLC bought a new stake in shares of Health Catalyst in the third quarter worth about $45,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Health Catalyst by 71.7% in the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock worth $47,000 after acquiring an additional 6,832 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Trading Up 7.7%

HCAT stock opened at $1.40 on Friday. The company has a market cap of $103.45 million, a P/E ratio of -0.38 and a beta of 1.63. Health Catalyst has a twelve month low of $0.96 and a twelve month high of $4.29. The company has a quick ratio of 1.69, a current ratio of 1.69 and a debt-to-equity ratio of 1.10. The business has a fifty day moving average of $1.26 and a 200-day moving average of $1.89.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Monday, May 11th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.01. The company had revenue of $70.76 million during the quarter, compared to the consensus estimate of $69.24 million. Health Catalyst had a negative return on equity of 3.52% and a negative net margin of 87.69%. As a group, equities research analysts expect that Health Catalyst will post -0.28 EPS for the current year.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.